Leaflet DARUNAVIR ALVOGEN 600mg film-coated tablets
Indicated for: HIV-1 infection
Route of administration: oral
Substance: darunavir (protease inhibitor)
ATC: J05AE10 (Antiinfectives for systemic use | Direct acting antivirals | Protease inhibitors)
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Darunavir is a protease inhibitor used for the treatment of human immunodeficiency virus (HIV) infection. It works by inhibiting the HIV protease enzyme, which is essential for viral replication, thereby reducing the viral load.
The medication is taken orally, usually once daily, in combination with other antiretroviral drugs. Common side effects include nausea, diarrhea, headaches, and skin rashes.
Darunavir is contraindicated in patients with hypersensitivity to the active substance or any of its excipients. It should also be used with caution in patients with severe hepatic conditions.
This medication is an important option for managing HIV infection, helping to improve patients' quality of life and prevent disease progression.
General data about DARUNAVIR ALVOGEN 600mg
- Substance: darunavir
- Date of last drug list: 01-08-2023
- Commercial code: W63665001
- Concentration: 600mg
- Pharmaceutical form: film-coated tablets
- Quantity: 60
- Product type: generic
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Pharmaceutical forms available for darunavir
Concentrations available for darunavir
- 100mg/ml
- 150mg
- 300mg
- 400mg
- 600mg
- 75mg
- 800mg